Volume | 398,945 |
|
|||||
News | - | ||||||
Day High | 3.81 | Low High |
|||||
Day Low | 3.62 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Sutro Biopharma Inc | STRO | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
3.64 | 3.62 | 3.81 | 3.71 | 3.76 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
5,142 | 398,945 | $ 3.72 | $ 1,484,169 | - | 2.005 - 6.13 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:32:32 | 1 | $ 3.96 | USD |
Sutro Biopharma Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
226.14M | 60.95M | - | 153.73M | -106.79M | -1.75 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Sutro Biopharma News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical STRO Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 4.35 | 4.4699 | 3.62 | 3.99 | 558,253 | -0.62 | -14.25% |
1 Month | 4.34 | 5.0895 | 3.62 | 4.32 | 833,198 | -0.61 | -14.06% |
3 Months | 3.97 | 6.13 | 3.20 | 4.36 | 1,015,754 | -0.24 | -6.05% |
6 Months | 3.17 | 6.13 | 3.06 | 4.35 | 918,729 | 0.56 | 17.67% |
1 Year | 5.18 | 6.13 | 2.005 | 4.10 | 735,698 | -1.45 | -27.99% |
3 Years | 18.34 | 23.70 | 2.005 | 6.68 | 573,460 | -14.61 | -79.66% |
5 Years | 11.79 | 28.30 | 2.005 | 9.10 | 440,784 | -8.06 | -68.36% |
Sutro Biopharma Description
Sutro Biopharma Inc is clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. |